Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22433813 | 0.93 | YAP1 (0.56) | YAP1MAPK1P2RX7PRMT5WDR77 | |
| SCHEMBL28610465 | 0.92 | PPARA (0.55) | YAP1MAPK1PPARAPRMT5WDR77 | |
| SCHEMBL28610466 | 0.92 | PPARA (0.55) | YAP1MAPK1PPARAPRMT5WDR77 | |
| SCHEMBL18788023 | 0.86 | YAP1 (0.60) | YAP1MAPK1P2RX7MAPTNTSR1 | |
| SCHEMBL20556236 | 0.86 | YAP1 (0.60) | YAP1MAPK1P2RX7MAPTNTSR1 | |
| SCHEMBL3008280 | 0.86 | YAP1 (0.60) | YAP1MAPK1P2RX7MAPTNTSR1 | |
| SCHEMBL12652625 | 0.86 | YAP1 (0.60) | YAP1MAPK1P2RX7MAPTNTSR1 | |
| SCHEMBL3008274 | 0.86 | YAP1 (0.60) | YAP1MAPK1P2RX7MAPTNTSR1 | |
| SCHEMBL24979441 | 0.86 | PPARA (0.48) | YAP1MAPK1P2RX7PPARA | |
| SCHEMBL28610469 | 0.86 | HTT (0.52) | YAP1MAPK1PPARAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | YAP1 1942/4885MAPK1 1114/4885P2RX7 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.